Osiris trumpets patchy Prochymal heart data, and extend trial duration
This article was originally published in Clinica
Executive Summary
Osiris's off-the-shelf stem cell treatment Prochymal (remestemcel-L) has shown some early promise in preventing heart failure in a Phase II trial in heart attack patients, the company says. But although the trial, with some 220 patients, is one of the largest stem cell studies ever undertaken, the top-line data released by the company are patchy and no figures for the primary endpoint measure of left ventricular end systolic volume have yet been given, clouding the true picture of the product's efficacy in the study until the full data are released.